Drug Overview

Amivantamab-vmjw is a first-in-class bispecific antibody designed to target specific genetic mutations in non-small cell lung cancer (NSCLC) that were previously difficult to treat. It represents a significant advancement in precision oncology by targeting two distinct pathways simultaneously.

Generic Name: Amivantamab-vmjw
US Brand Names: Rybrevant®
Drug Class: Bispecific Antibody (EGFR and MET Inhibitor)
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: Approved for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, and recently (2024) approved in combination with lazertinib for first-line treatment of common EGFR mutations (Exon 19 del/L858R).

What Is It and How Does It Work? (Mechanism of Action)

Amivantamab is a “bispecific” antibody, meaning it has two different arms that bind to two different targets on the surface of cancer cells.

Dual Targeting: One arm binds to EGFR (Epidermal Growth Factor Receptor) and the other binds to MET (Mesenchymal-Epithelial Transition factor). Both are proteins that drive tumour growth.
Three Distinct Mechanisms:
1. Ligand Blocking: It blocks the natural ligands from binding to EGFR and MET, preventing the growth signals from entering the cell.
2. Receptor Degradation: It triggers the internalisation and degradation of these receptors, removing them from the cell surface.
3. Immune Engagement (Trogoctyosis): It recruits immune cells (monocytes and macrophages) to the tumour. Through a process called “trogocytosis” (nibbling), these immune cells eat away at the tumour cell membrane, leading to cell death.

FDA-Approved Clinical Indications

Amivantamab has expanded its indications from a niche rescue therapy to a frontline option.

Oncological Uses:

EGFR Exon 20 Insertion NSCLC: For adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
First-Line EGFR-Mutated NSCLC: In combination with lazertinib (Lazcluze), it is approved for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Previously Treated EGFR-Mutated NSCLC: In combination with chemotherapy (carboplatin/pemetrexed) for patients who have progressed on EGFR tyrosine kinase inhibitors (like osimertinib).

Non-Oncological Uses:

There are no FDA-approved non-oncological indications.

Dosage and Administration Protocols

Amivantamab requires a specific infusion protocol to manage reactions. The dose is based on body weight.

Standard Oncology Dosage:

Baseline Weight < 80 kg: 1050 mg
Baseline Weight ≥ 80 kg: 1400 mg
Frequency: Weekly for the first 4 weeks (Cycle 1), then every 2 weeks starting at Week 5.

Infusion Schedule (Split Dose Week 1):

Week 1 Day 1: Administer only part of the dose (350 mg) to check for reactions.
Week 1 Day 2: Administer the remainder of the dose (700 mg or 1050 mg, depending on weight).
Premedication: Mandatory antihistamines, acetaminophen, and corticosteroids are required before the initial infusions to prevent reactions.

Renal/Hepatic Adjustments:

Renal Impairment: No dose adjustment needed for mild/moderate impairment.
Hepatic Impairment: No dose adjustment needed for mild/moderate impairment.

Clinical Efficacy and Research Results

Clinical trials from 2020-2025 have established Amivantamab as a superior option to traditional therapies for specific mutations.

First-Line Superiority (MARIPOSA Trial): In patients with common EGFR mutations (Exon 19 del/L858R), the combination of Amivantamab + Lazertinib reduced the risk of disease progression or death by 30% compared to osimertinib (the current standard). The median Progression-Free Survival (PFS) was 23.7 months vs 16.6 months for osimertinib.
Exon 20 Insertions (CHRYSALIS Trial): In this difficult-to-treat population, amivantamab showed an Overall Response Rate (ORR) of 40%, with a median duration of response of 11.1 months, significantly outperforming historical chemotherapy benchmarks.

Safety Profile and Side Effects

Important Warning:

Infusion-Related Reactions (IRR) Amivantamab causes Infusion-Related Reactions in a high percentage of patients (approx. 67%), mostly during the very first infusion. Symptoms include chills, fever, nausea, and shortness of breath. The split-dosing schedule in Week 1 is designed to mitigate this.

Common Side Effects (>10%)

Dermatologic: Rash (acneiform dermatitis) and paronychia (infection around fingernails) are very common (76%).
General: Fatigue and oedema (swelling).
Gastrointestinal: Nausea, constipation, and vomiting.
Musculoskeletal: Muscle and joint pain.
Laboratory Abnormalities: Decreased albumin, increased liver enzymes (ALT/AST).

Serious Adverse Events

Interstitial Lung Disease (ILD): Pneumonitis can occur (approx. 3%). Patients with new respiratory symptoms need immediate evaluation. Permanently discontinue if ILD is confirmed.
Ocular Toxicity: Keratitis and visual impairment have been reported. Eye exams may be necessary.
Venous Thromboembolism (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE) risk is increased, especially when combined with lazertinib. Prophylactic anticoagulation is often recommended for the first 4 months of combination therapy.

Management Strategies:

For Rash: Use alcohol-free emollients and sunscreen. Topical corticosteroids or oral antibiotics (doxycycline) may be prescribed prophylactically.
For IRRs: Stop the infusion immediately for severe reactions. Resume at 50% rate once resolved.

Connection to Stem Cell and Regenerative Medicine

Amivantamab’s dual mechanism links it to regenerative pathways involving growth factors.

Targeting Cancer Stem Cells: The MET pathway is known to drive “stemness” and drug resistance in cancer cells. By blocking MET, amivantamab may target the population of cancer stem cells that survive EGFR inhibition, preventing tumour regrowth.
Immune Modulation: Research (2024) indicates amivantamab can synergise with other immunotherapies (like pembrolizumab) to enhance the infiltration of cytotoxic T-cells into the tumour microenvironment, effectively “warming up” cold tumours.

Patient Management & Practical Recommendations

Pre-Treatment Tests:

Genetic Testing: Confirmation of EGFR mutation status (Exon 20 insertion, Exon 19 del, or L858R) via an FDA-approved test is mandatory.
Pregnancy Test: Verify negative status in females of reproductive potential.
Skin Assessment: Baseline check for pre-existing skin conditions due to high risk of rash.

Precautions During Treatment:

Sun Protection: Strict sun protection (hats, sunscreen) is required during and for 2 months after treatment to prevent severe skin rash.
Nail Care: Keep fingernails clean and trimmed to prevent paronychia (infection). Soaking nails in diluted vinegar may help.

Do’s and Don’ts:

DO: Allow extra time for the first infusion appointment (split over 2 days) as it is lengthy and requires observation.
DO: Report any vision changes or eye pain to your oncologist immediately.
DON’T: Stop taking the medication if you develop a rash without consulting your doctor; specific creams can manage this common side effect.
DON’T: Use heavy creams or makeup that can clog pores, worsening the acne-like rash.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.